The ISTAND program is designed to advance promising, high-impact New Approach Methodologies (NAMs) through structured FDA engagement to inform regulatory decision-making. Acceptance of Axion’s LOI ...

Salt Lake City, Utah, February 9, 2026 – Carterra Inc., the leading provider of technologies enabling high-throughput biology, today announced the launch of the Carterra Vega High-Throughput Surface ...

As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.

Twenty years ago, drug discovery ran on a simple script of screening compounds and hoping for a hit. This exclusive ebook, ...

The biotechnology industry is moving past the initial excitement of artificial intelligence (AI) to confront a more complex reality: the transition from isolated digital tools to fully integrated, ...

Over the past decade, few areas of medicine have captured both scientific and public attention as dramatically as GLP-1 (glucagon-like peptide-1)-based therapies. First developed for diabetes, GLP-1 ...

Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that ...

Traditional animal models remain an important part of preclinical research, but species differences can limit translation of ...

Amyotrophic lateral sclerosis (ALS) is a form of motor neuron disease (MND) in which the motor neurons are gradually lost. As these neurons deteriorate, patients experience muscle weakness, twitching, ...

Priyom Bose earned her Ph.D. in Plant Biology and Biotechnology from the University of Madras, India, in 2019 before ...

A scientist who assumes there is one authoritative FDA AI drug development guidance document to read would be forgiven, and wrong. The reality is closer to a paper trail: a 2021 action plan that most ...